Medicine
Brenzavvy 20 mg tablet
Brenzavvy 20 mg tablet is a prescription medicine containing Bexagliflozin for oral use, marketed by TheracosBio, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store from 20 °C to 25 °C (68 °F to 77 °F), excursions permitted between 15 °C…
Key facts
- Active ingredient (INN)
- Bexagliflozin
- Brand
- Brenzavvy
- Strength
- 20 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 30 tablets, 90 tablets
- Marketing authorisation holder
- TheracosBio
- Manufacturer
- TheracosBio
- Origin register
- US FDA, United States
- Storage
- Store from 20 °C to 25 °C (68 °F to 77 °F), excursions permitted between 15 °C to 30 °C (59 °F to 86 °F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 13 July 2023
- Identifiers
- RxCUI 2637859, 2637865DailyMed set ID 3cdf28fc-4194-4ad6-aa03-c9eaa68da83eNDC 82381-2174Application NDA214373
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet in 1 bottle | 82381-2174-1 | TheracosBio | 13 July 2023 |
| 90 tablet in 1 bottle | 82381-2174-2 | TheracosBio | 13 July 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 20 January 2023 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Bexagliflozin 20 mg tablet.
Clinical summary
Bexagliflozin is a sodium-glucose cotransporter 2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is available as tablets for oral use. MedsAcross supplies Bexagliflozin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about BexagliflozinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Bexagliflozin prescribing information (TheracosBio) · U.S. National Library of Medicine, DailyMed
Need Brenzavvy 20 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.